

## Faculty Panel Outline:

- **Myeloma Case Study #1 Introduction** presented by Krina K. Patel, MD, MSc  
– *The University of Texas MD Anderson Cancer Center*
- **Lymphoma Case Study #2 Introduction** presented by Loretta J. Nastoupil, MD  
– *The University of Texas MD Anderson Cancer Center*
- **Bridging Therapy for CAR T cells and Role of Radiation:**  
Chelsea C. Pinnix, MD, PhD – *The University of Texas MD Anderson Cancer Center* and Joanna C. Yang, MD, MPH – *Washington University*
- **Outpatient Cellular Therapy:**  
Yi Lin, MD, PhD – *Mayo Clinic*
- **Infectious Complications:**  
Tania Jain, MBBS – *Johns Hopkins Medicine*  
Zainab Shahid, MD, FACP – *University of North Carolina at Chapel Hill*
- **Survivorship/QOL/ePRO:**  
Surbhi Sidana, MD – *Stanford University*

With additional insight from Hans Lee, MD – *The University of Texas MD Anderson Cancer Center* and Tycel J. Phillips, MD – *University of Michigan Health*

# Case 1: Primary refractory DLBCL

- A 72-year-old man with PMH of type 2 DM and CKD (GFR: 40 ml/min) was diagnosed with **bulky stage IV DLBCL with positive cMYC** translocation without BCL2 and Bcl6.
- Treatment history:
  - **R-CHOP** x 4 → disease progression (kinetic failure)
  - **R-ICE** x 2 → No response

His treating Oncologist calls you for referral and planning next stage. He lives 3 hours away from your center.

# Case 2: Relapsed refractory MM

- A **69-year-old** woman with PMH of COPD and hypertension was diagnosed with **stage III (R-ISS) IgG lambda MM with t(4;14)**.
- Treatment History:
  - **VRD x 4 followed by Melph auto-SCT** with VGPR 3 months post transplant.
  - **Maintenance with Bortezomib** every 2 weeks → Disease progression one year post auto-SCT
  - **Daratumumab plus Dex** x 3 cycles → No response
  - **Elotuzumab, pomalidomide, and dexamethasone (EPd)** → with transient response.
  - Enrolled in a **BCMA T cell redirector trial**: → VGPR x 8 months then progressed